

The Second Messengers Ca^{2+} and cAMP as Potential Therapeutic Targets for the Control of Cancer Progression

E

ÁR~|~ÁGÉÁGÉFİLÁ

ÁR~|~ÁÍÉÁGÉFİLÁ

R~|~ÁFÍÉÁGÉFÍ

the pharmacology manipulation leading to decreased of intracellular Ca^{2+} levels, and increasing of cAMP, can help to reduce the development of the intrinsic resistance of the tumors by conventional antitumor protocols. we suggest that the pharmacological control of the intracellular levels of Ca^{2+} and cAMP may decrease the rate of tumor growth, invasion and metastasis strategy, combined with conventional antitumor treatments, may help reduce the dose of existing drugs in the treatment of tumors, reducing the adverse and the rate of abandoned therapy.

References

1. Sagar B, Lin YS, Castel LD (2017) Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a six-month episode: an economic analysis from the payer perspective. *J Med Econ* 5:1-15
2. Hanjani JM, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, et al. (2017) Tracking the evolution of non-small-cell lung cancer. *N Engl J Med* 376:2109-21.
3. Morigi C (2017) Highlights from the 15th Gallen International Breast Cancer Conference 15-18 march, 2017, Vienna: tailored treatments for patients with early breast cancer. *Ecancermedicalscience* 11: 732.
4. Eagles JR, Jimeno A (2016) Comimetib: Inhibiting MEK1/2 in BRAF V600-mutant melanoma. *Drugs Today (Barc)* 52: 593-605
5. Groenendyk J, Lynch J, Michalak M (2004) Calreticulin, Ca^{2+} , and calcineurin-signaling from the endoplasmatic reticulum. *Mol Cells* 17: 383-89
6. Frieden M, Amaudeau S, Castelbou C, Demareux N (2005) Subplasmalemmal mitochondria modulate the activity of plasma membrane Ca^{2+} ATPases. *J Biol Chem* 280: 43198-208. doi: 10.1074/jbc.M508120050